Third Rock Ventures III, L.P.
Known title: 10% OwnerCIK: 0001569705
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RVMD RASONQUE Receives Positive EU CHMP Opinion. The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.
Transaction History
| VYGR | ▼ Sell | Other | 1,500,000 | — | 2/2/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 128,642 | $1.2M | 2/1/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 185,000 | $1.7M | 1/31/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 75,000 | $677K | 1/30/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 50,000 | $451K | 1/27/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 50,000 | $461K | 1/25/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 100,000 | $927K | 1/24/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 55,000 | $498K | 1/23/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 100,000 | $915K | 1/20/2023 | View on chart |
| FULC | ▼ Sell | Other | 2,000,000 | — | 12/13/2022 | View on chart |
| PLRX | ▼ Sell | Other | 2,000,000 | — | 11/29/2022 | View on chart |
| PLRX | ▼ Sell | Other | 2,000,000 | — | 9/20/2022 | View on chart |
| VYGR | ▼ Sell | Open Market | 200,000 | $1.2M | 8/25/2022 | View on chart |
| VYGR | ▼ Sell | Open Market | 149,972 | $913K | 8/24/2022 | View on chart |
| VYGR | ▼ Sell | Open Market | 128,456 | $776K | 8/16/2022 | View on chart |
| VYGR | ▼ Sell | Open Market | 135,808 | $820K | 8/15/2022 | View on chart |
| VYGR | ▼ Sell | Open Market | 348,007 | $2.1M | 8/12/2022 | View on chart |
| RVMD | ▼ Sell | Open Market | 419,901 | $8.5M | 6/8/2022 | View on chart |
| FULC | ▼ Sell | Other | 1,000,000 | — | 11/10/2021 | View on chart |
| FULC | ▼ Sell | Other | 1,000,000 | — | 9/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Pliant Therapeutics Names New Chief Medical Officer
Pliant Therapeutics has appointed David Raben, M.D., as its new Chief Medical Officer. This leadership change is a standard corporate update for the company. The stock is currently trading within its 52-week range, with recent technical indicators showing a support rejection near $1.13.
Pliant Therapeutics Names New Chief Medical Officer. Pliant Therapeutics has appointed David Raben, M.D., as its new Chief Medical Officer. This leadership change is a standard corporate update for the company. The stock is currently trading within its 52-week range, with recent technical indicators showing a support rejection near $1.13.